File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1744-4667.2012.00096.x
- WOS: WOS:000218051600004
- Find via
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Article: Prescription drug use in pregnancy: more evidence of safety is needed
Title | Prescription drug use in pregnancy: more evidence of safety is needed |
---|---|
Authors | |
Keywords | Antidepressants Anti-epileptic drugs Congenital malformation Medicines and Healthcare products Regulatory Agency US Food and Drug Administration |
Issue Date | 2012 |
Publisher | Royal College of Obstetricians and Gynaecologists. The Journal's web site is located at http://onlinetog.org |
Citation | The Obstetrician & Gynaecologist, 2012, v. 14 n. 2, p. 87-92 How to Cite? |
Abstract | Key content:
Prescription drug use during pregnancy is prevalent, with 44–99% of women being prescribed medication during pregnancy.
Pregnant women and their unborn children are considered a vulnerable population; recent public health scares, such as H1N1, have highlighted the need for more detailed research into medication use in pregnancy.
The teratogenic risk of more than 80% of 468 drugs released in the USA over the last 20 years remains to be clarified.
Maternal physiological changes during pregnancy can alter drug pharmacokinetics, with poorly understood effects, while placental transfer of medications may have unknown fetal consequences.
There is an urgent need for further research into the adverse effects of drugs used in pregnancy.
Learning objectives:
To know about the prevalence of prescription medication use during pregnancy.
To be aware of the lack of safety data available on fetal adverse effects for commonly prescribed drugs.
Ethical issues:
Drug companies are reluctant to carry out phase III clinical trials in pregnant women and they rely on animal models and post-marketing surveillance for the identification of adverse effects.
Is it unethical to prescribe drugs in pregnancy for which there is little concrete safety data? |
Persistent Identifier | http://hdl.handle.net/10722/164489 |
ISSN | 2023 Impact Factor: 1.2 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, M | en_US |
dc.contributor.author | Wong, ICK | en_US |
dc.contributor.author | Sutcliffe, AG | en_US |
dc.date.accessioned | 2012-09-20T08:00:21Z | - |
dc.date.available | 2012-09-20T08:00:21Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | The Obstetrician & Gynaecologist, 2012, v. 14 n. 2, p. 87-92 | en_US |
dc.identifier.issn | 1467-2561 | - |
dc.identifier.uri | http://hdl.handle.net/10722/164489 | - |
dc.description.abstract | Key content: Prescription drug use during pregnancy is prevalent, with 44–99% of women being prescribed medication during pregnancy. Pregnant women and their unborn children are considered a vulnerable population; recent public health scares, such as H1N1, have highlighted the need for more detailed research into medication use in pregnancy. The teratogenic risk of more than 80% of 468 drugs released in the USA over the last 20 years remains to be clarified. Maternal physiological changes during pregnancy can alter drug pharmacokinetics, with poorly understood effects, while placental transfer of medications may have unknown fetal consequences. There is an urgent need for further research into the adverse effects of drugs used in pregnancy. Learning objectives: To know about the prevalence of prescription medication use during pregnancy. To be aware of the lack of safety data available on fetal adverse effects for commonly prescribed drugs. Ethical issues: Drug companies are reluctant to carry out phase III clinical trials in pregnant women and they rely on animal models and post-marketing surveillance for the identification of adverse effects. Is it unethical to prescribe drugs in pregnancy for which there is little concrete safety data? | - |
dc.language | eng | en_US |
dc.publisher | Royal College of Obstetricians and Gynaecologists. The Journal's web site is located at http://onlinetog.org | - |
dc.relation.ispartof | The Obstetrician & Gynaecologist | en_US |
dc.subject | Antidepressants | - |
dc.subject | Anti-epileptic drugs | - |
dc.subject | Congenital malformation | - |
dc.subject | Medicines and Healthcare products Regulatory Agency | - |
dc.subject | US Food and Drug Administration | - |
dc.title | Prescription drug use in pregnancy: more evidence of safety is needed | en_US |
dc.type | Article | en_US |
dc.identifier.email | Wong, ICK: wongick@hku.hk | en_US |
dc.identifier.authority | Wong, ICK=rp01480 | en_US |
dc.identifier.doi | 10.1111/j.1744-4667.2012.00096.x | - |
dc.identifier.hkuros | 207225 | en_US |
dc.identifier.volume | 14 | en_US |
dc.identifier.issue | 2 | en_US |
dc.identifier.spage | 87 | en_US |
dc.identifier.epage | 92 | en_US |
dc.identifier.isi | WOS:000218051600004 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 1467-2561 | - |